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Summary
Cell senescence is a permanent growth arrest following extended proliferation. Cultured cancer cells including
metastatic melanoma cells often appear immortal (proliferate indefinitely), while uncultured benign nevi
(moles) show senescence markers. Here, with new explantation methods, we investigated which classes of
primary pigmented lesions are typically immortal. Nevi yielded a few proliferating cells, consistent with most
nevus cells being senescent. No nevus culture (0 ⁄28) appeared immortal. Some thin and thick melanoma cul-
tures proved immortal under these conditions, but surprisingly few (4 ⁄37). All arrested cultures displayed
three senescence markers in some cells: b-galactosidase, nuclear p16, and heterochromatic foci ⁄aggregates.
However, melanoma cultures also showed features of telomeric crisis (arrest because of ultrashort telomeres).
Moreover, crisis markers including anaphase bridges were frequent in uncultured vertical growth-phase (VGP)
melanomas. Conversely, all immortal melanoma cultures expressed telomerase reverse transcriptase and
telomerase, showing aneuploidy. The findings suggest that primary melanomas are typically precrisis, with
immortalization ⁄ telomere maintenance as a late event.
Introduction
Cell senescence, a form of permanent growth arrest,
has emerged as a central mechanism of tumor suppres-
sion and a potential source of therapeutic targets for
diverse malignancies. Normal mammalian somatic cells
enter senescence following either extensive proliferation
(replicative senescence), activation of an oncogene
(oncogene-induced senescence), or cellular stresses
including oxidative or DNA damage (d’Adda di Fagagna,
Significance
Cell senescence is a major tumor suppressor mechanism and a target of familial melanoma genes, while
conversely, immortality is widely considered a hallmark of cancer. However, it is unclear whether early can-
cers are immortal, because most cultured lines arise from advanced cancers. We tested this using improved
culture conditions and found unexpectedly that many primary melanomas, despite growing well, eventually
arrested. This difference from the previously reported behavior of many metastatic melanomas suggests
prognostic value for markers of immortality. We also observed that cells from radial growth-phase (RGP)
melanomas consistently require keratinocyte products for survival, potentially explaining their thin form.
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2008; Collado et al., 2005; Mooi and Peeper, 2006;
Stewart and Weinberg, 2006). Cells of various kinds of
benign, static neoplasms in vivo show markers of
senescence, for example, in melanocytic nevi, which
generally carry activating v-raf murine sarcoma viral
oncogene homolog B1 (BRAF) or neuroblastoma RAS
viral oncogene homolog (NRAS) mutations (Gray-Schop-
fer et al., 2006; Michaloglou et al., 2005). It is proposed
that clonal proliferation initiated by an oncogene is nor-
mally limited by oncogene-induced senescence, giving a
benign lesion rather than a growing cancer (Bennett and
Medrano, 2002; Feldser and Greider, 2007; Gray-Schop-
fer et al., 2006; Michaloglou et al., 2005; Mooi and Pee-
per, 2002). Moreover, in human cells, escape from
senescence usually leads to a further kind of arrest
called telomeric crisis, another barrier to immortality
(Artandi and DePinho, 2010; Bond et al., 1999). Mela-
noma, now the sixth commonest cancer in the UK fol-
lowing progressive increases in incidence and mortality
(CR-UK Statistical Information Team, 2010), is an ame-
nable research model for senescence, crisis, and
immortalization in cancer progression, as early melano-
mas and their potential precursor lesions, nevi, are
accessible and are treated by excision. The main aim of
this study was to find out at which stage in melanoma
progression melanocytes typically become immortal.
Several signaling pathways can mediate cell senes-
cence (reviews: Cichowski and Hahn, 2008; d’Adda di
Fagagna, 2008). Telomere shortening is strongly impli-
cated in human replicative senescence: DNA-damage
signaling from short telomeres activates p53, transcrip-
tionally upregulating the cyclin-dependent kinase inhibi-
tor (CDKI) p21 (d’Adda di Fagagna, 2008; Collado et al.,
2007; Herbig and Sedivy, 2006). Replicative and onco-
gene-induced senescence also often involve another
major tumor suppressor and CDKI, p16 [inhibitor A of
kinase 4 (INK4A)] (Bond et al., 1999; Herbig and Sedivy,
2006; Jacobs and de Lange, 2005; Serrano et al., 1997).
p16 upregulation can involve BMI1 (Itahana et al., 2003)
and ⁄or JMJD3 (Barradas et al., 2009). p16 affects per-
manent cell arrest by inhibiting cyclin-dependent kinase
4 (CDK4) and CDK6 and thereby activating the retino-
blastoma (RB) family of growth inhibitors.
p16 is encoded at the locus most commonly mutated
in familial melanoma, CDKN2A, underlining its impor-
tance in melanoma (Bennett, 2008; Gray-Schopfer and
Bennett, 2006; Ha et al., 2008; Mooi and Peeper, 2006).
CDKN2A also encodes another protein, alternative read-
ing frame (ARF), another effector of senescence (Ha
et al., 2008), although not clearly so in human cells (Wei
et al., 2001). Melanoma-associated mutations of p16
were confirmed to disable cell senescence in melanoma
cells (Haferkamp et al., 2008).
It is generally proposed that cellular immortalization
(acquired ability to divide indefinitely) is required for can-
cer development (Bennett, 2003; Collado et al., 2007;
Mooi and Peeper, 2006; Stewart and Weinberg, 2006).
However, this has not been proven for all types of can-
cer, especially early cancers. In the case of melanoma,
many immortal cell lines have been derived from meta-
static melanomas, but fewer from primary melanomas
(Herlyn et al., 1985a; Hsu et al., 2000; Pope et al., 1979;
Semple et al., 1982). Primary cutaneous melanocytic
lesions can be classified into four stages: benign nevi or
moles, dysplastic nevi, radial growth-phase (RGP) mela-
nomas, which grow in the epidermis with micro- or no
invasion, and vertical growth-phase (VGP) melanomas,
which invade the deeper dermis and appear competent
for metastasis (Clark et al., 1989; Herlyn et al., 1985a).
The molecular requirements for immortalization spe-
cifically of human melanocytes have been established in
recent years. As expected from its role in melanoma
susceptibility, p16 appears important and defects in the
p16 ⁄RB pathway in melanocytes lead to lifespan exten-
sion; however, the cells can then still become arrested,
by a p53-dependent route (Sviderskaya et al., 2003).
Human melanomas, while often retaining wild-type p53,
may show downstream suppression of p53 signaling by
various routes including TBX2 or DEK overexpression or
LKB1 ⁄STK11 deficiency (Khodadoust et al., 2009);
review: (Bennett, 2008). However, disruption of both
the RB and p53 pathways is still not sufficient for
immortalization. Human cells (including melanocytes)
that evade the normal senescence pathways yet lack
telomerase can resume division and telomere shorten-
ing but reach a further growth barrier called telomeric
crisis. This can be defined as the state resulting in a cell
population from loss of telomere function following
extreme shortening (Artandi and DePinho, 2010; Chin
et al., 2004). It is a stage of continuing cell division bal-
anced by extensive cell death, as the unprotected chro-
mosome ends can be ligated to each other by the DNA
repair machinery. Ligated chromosomes lead to ana-
phase bridging [a dicentric chromosome(s) attached to
both poles] and thence mitotic catastrophe, chromo-
somal breakages, and rearrangements (Artandi and DeP-
inho, 2010; Bond et al., 1999; DePinho and Polyak,
2004; Gisselsson and Ho¨glund, 2005). Telomeric crisis
has been described as a stage in the progression of
human breast, pancreatic, colorectal, and other cancers
(Chin et al., 2004; Hezel et al., 2006; Ho¨glund et al.,
2003; Rudolph et al., 2001). Escape from telomeric cri-
sis, in culture or in cancer development, requires telo-
mere maintenance, which permits immortality and
which is usually achieved, either as a rare natural event
(in cancers) or artificially, by upregulated expression
of telomerase reverse transcriptase (TERT), the cata-
lytic subunit of telomerase (Bennett, 2008; Bond
et al., 1999; DePinho and Polyak, 2004; Newbold, 2002;
Wynford-Thomas, 1999). Telomere maintenance com-
bined with a defect in the p16 ⁄RB pathway appears
necessary and sufficient for full immortalization of
human melanocytes (Gray-Schopfer et al., 2006;
Sviderskaya et al., 2003).
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We became interested to determine whether immor-
tality arises at a particular stage in melanoma progres-
sion. There is some information on the acquisition of
the required changes, RB lesions, and telomerase acti-
vation. p16 expression appears typically strong in benign
nevi, reduced in dysplastic nevi and RGP melanomas,
and lost (as nuclear p16) in VGP melanomas (Gray-
Schopfer et al., 2006; Keller-Melchior et al., 1998; Talve
et al., 1997). Several groups report high telomerase
activity in cells from metastatic melanomas, but reports
differ regarding telomerase activity in primary lesions
(Carvalho et al., 2006; Glaessl et al., 1999; Rudolph
et al., 2000). We previously proposed a model in which
benign nevi show oncogene-induced senescence and
melanoma is initiated by immortalization, through
p16 ⁄RB deficiency and telomerase expression (Bennett,
2003; Gray-Schopfer and Bennett, 2006). Marker studies
are consistent with this (Gray-Schopfer et al., 2006; Mic-
haloglou et al., 2005) but have not definitively shown
which lesions are immortal; thus, the idea that nevi are
senescent has been questioned (Cotter et al., 2007).
Previous culture studies have not given definitive
answers regarding which pigmented lesions are immor-
tal. Proliferating cells in nevus cultures (Halaban et al.,
1986; Mancianti et al., 1988) might have been normal
melanocytes, as these were not excluded, and in
descriptions of cultured RGP and VGP melanoma cells
(e.g. Herlyn et al., 1985b; Hsu et al., 2000), only estab-
lished lines were well characterized, leaving it unclear
whether other cultures arrested. Explantation with
extended cell culture is the best available routine assay
to test for immortality, because even once established
as immortal cultured lines, RGP and early VGP cells are
usually poorly or non-tumorigenic in immunodeficient
mice (Hsu et al., 2000; Kobayashi et al., 1994).
Thus, to test explicitly at what clinical stage(s) in mel-
anoma development immortality appears, we have
made new primary cultures to study culture lifespan
(though this is slow and laborious; this report summa-
rizes over 4 years’ work.) Re-examining growth require-
ments, we developed conditions in which cells of all
four lesion types showed good initial viability and
growth. In summary, despite this initial growth, no
benign or dysplastic nevus culture was immortal, and
surprisingly, only a minority of primary melanoma cul-
tures were immortal under these conditions. Combined
data from their phenotypes and in vivo markers suggest
that arrest of melanoma cultures reflected telomeric cri-
sis rather than senescence.
Results
Favorable culture conditions for typical melanocytic
lesional cells
Melanomas and dysplastic nevi are frequently deficient
in the p16 ⁄RB pathway (Gray-Schopfer et al., 2006).
Therefore, the initial culture conditions tested were
adapted from those developed for p16-deficient melano-
cytes, which have a high apoptotic tendency and require
either keratinocytes or keratinocyte-derived factors for
survival (Sviderskaya et al., 2003). Features included
mitomycin-inactivated mouse keratinocyte feeder cells
and a neutral pH medium containing fetal calf serum
(FCS), 12-O-tetradecanoyl phorbol 13-acetate (TPA),
cholera toxin (CT), and stem cell factor (SCF), which is
secreted by human keratinocytes. Despite the very
small size of samples, estimated to yield typically
around 103–105 viable lesional cells in all, these condi-
tions yielded healthy appearing melanocytic cells from
nearly all samples of all lesion types (Figure 1). These
Figure 1. Initial morphology of cells from
different stages of progression. Phase-
contrast images of cells of each lesion
type at low passage levels. BN: a benign
nevus at passage 1 (primary explant
culture being passage 0), showing highly
dendritic cells (arrows). K: keratinocyte
feeder cells. DN: dysplastic nevus,
passage 1. Polydendritic cells (arrows) as
well as bipolar and oligodendritic cells.
RGP: radial growth-phase melanoma
(SGM3), passage 1. Large, well-pigmented
cells were present in this example
(arrows). VGP: vertical growth-phase
melanoma (SGM5), passage 3. Typically
cells were smaller than for other lesion
types and bipolar or tripolar. Quite similar
to normal growing melanocytes but
dendrites wider. Scale bar for all panels:
150 lm.
Soo et al.
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were presumably virtually all lesional cells, as the
epidermis with normal melanocytes was excluded (or
cultured separately). Fibroblast contamination was rare;
cultures with fibroblasts were discarded and not
analyzed here, as they overgrew the lesional cells.
Some keratinocytes attached initially from epidermal
explants but did not proliferate in this medium.
The appearance of the cultures was very variable, but
differences between lesion types emerged. Benign and
dysplastic nevus cells often resembled senescent cul-
tured melanocytes: large, non-dividing, flat, or multiden-
dritic cells (Figure 1). Other nevus cultures initially
yielded some growing melanocytes (bi- or tripolar),
which acquired a senescent appearance only after one
or more passages (Figure S1). Initial growth was,
however, often in the form of colonies, suggesting that
only a small fraction of explanted cells were capable of
proliferation. Senescent cultured melanocytes often
attach poorly after subculture, so this may likewise be
true of senescent cells ex vivo.
Melanoma cultures initially tended to have fewer
senescent-looking cells (Figure 1). Preliminary experi-
ments suggested that CT and SCF promoted the
growth of nevus and RGP melanoma cultures and that
200 nM TPA was an optimal level, just as for normal
melanocytes (Bennett et al., 1985, 1987). Cultures
were therefore provisionally grown and passaged in
the initial medium, giving stocks for quantitative experi-
ments, which gave similar results. Figure 2A shows
two typical experiments with an RGP culture, indicating
higher net growth with SCF as well as TPA and CT,
slightly further improved by endothelin 1 (EDN1),
another keratinocyte product. EDN1 was not, however,
routinely added at explantation because it is also a
mitogen for fibroblasts. Omission of either TPA or CT
also reduced net growth. Keratinocyte feeder cells did
not improve growth compared to the four factors (at
the tested cell densities). Longer-term growth curves
for two RGP cultures showed markedly more growth
with the four supplements compared to TPA + CT only
(Figure 2B and data not shown). RGP melanoma cells
consistently showed substantial rates of apoptosis in
the absence of SCF and EDN1 (Figure 2C), as seen
previously with p16-deficient but not normal melano-
cytes (Sviderskaya et al., 2003). (This is consistent with
the known frequent defects of the p16 ⁄RB pathway in
melanoma cells.) RGP cells gave biphasic dose–
response curves to TPA, with 200 nM generally opti-
mal for growth (Figure 2D), as with normal human and
mouse melanocytes (Bennett et al., 1985, 1987). While
some RGP cells grew equally well with 20 nM TPA
(data not shown), 200 nM TPA was adopted as rou-
tine. We thus retained the initial tested conditions for
routine nevus and RGP cultures. VGP cell growth,
however, appeared best with 20–40 nM TPA (Fig-
ure 2D), so 40 (later 20) nM TPA was adopted for VGP
cultures.
Culture lifespan and cell senescence
Growth curves were derived from cell counts over the
lifespan of each culture (or for a year or more) to iden-
tify senescence or immortality. Some cultures failed to
grow sufficiently for any subculture, while others were
subcultured. Various types of growth kinetics were
observed: most commonly proliferation and then arrest
(Figure 3A,B and D), alternatively slow growth and
then acceleration (Figure 3C), or deceleration and then
acceleration [St. George’s melanoma (line) 2 (SGM2) in
Figure 3C]. Acceleration suggests ‘progression’ in cul-
ture – the acquisition of additional genetic or epigenetic
changes facilitating growth. It may also represent selec-
tion, for example, the epidermal portion of line SGM4
accelerated a few weeks after the dermal portion,
A C
DB
Figure 2. Factor dependence retained by radial growth-phase
(RGP) melanoma cells. Key: C: CT, 200 pM. E: EDN1, 10 nM. F:
XB2 feeder cells. S: SCF, 10 ng ⁄ ml. T: TPA, 200 nM. (A) Response
to combinations of mitogens. SGM2 RGP cells at passage 15 were
plated at 3 · 104 cells ⁄ ml with the indicated combinations of
factors and grown for 7 or 10 days as indicated (two separate
experiments), with medium changes every 3–4 days. Cells were
harvested and counted; means and SEM of triplicate dishes are
shown. (B) Longer time course of response to SCF and EDN1.
SGM4 cells were grown with and without these factors for several
passages. Triplicate cultures were counted after each passage and
the fold increase was calculated. These were multiplied to obtain
total fold increase. Substantially better growth with SCF and EDN1.
Similar results were obtained with RGP line SGM3, except this line
grew more slowly under both conditions. (C) High apoptotic rates
of three RGP lines (SGM2-4), suppressed by stem cell factor (SCF)
and EDN1. Cells were grown for about 5 weeks with and without
SCF and EDN1, and then the TUNEL method was used to assess
% apoptotic cells (Methods). Means and SEM of triplicate cultures
are shown. (D) Dose-response of cell numbers to TPA in typical
RGP and vertical growth-phase (VGP) cultures. RGP cells (SGM1)
or VGP cells (SGM5) were plated at 3 · 104 ⁄ ml and grown for
7 days with SCF, cholera toxin, and the stated amounts of 12-O-
tetradecanoyl phorbol 13-acetate (TPA). Means and SEM of
triplicate counts are shown. Note that SGM5 cells reached higher
densities than other strains; so for this line, the RPMI 1640
medium was mixed 50:50 with DMEM to avoid acidification.
Counts for cultures with 20 nM TPA gave no significant difference
between this mixture and 100% RPMI 1640 at day 7 (not shown).
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suggesting that immortal cells were already present
in both portions at explantation, and took over both
cultures.
Table 1(A) shows the aggregated culture-lifespan data
for lesions of all types. In summary, it can be seen that
no benign or dysplastic nevus cultures showed numer-
ous doublings nor immortality. RGP and VGP melanoma
cultures proliferated for a wide range of different peri-
ods up to about 6 months but then (surprisingly) also
typically became arrested. Arrested cells tended to
become large and flat or multidendritic. Only about one
in nine cultures of primary melanoma cells continued to
proliferate indefinitely (for at least a year) without senes-
cence and was thus taken to be immortal.
Where cultures arrested, the final cell yield was typi-
cally modest, about 102–106 cells, because starting
numbers were low and the giant arrested cells did not
reattach efficiently after subculture. Thus characterization
generally had to involve small-scale methods like immu-
nostaining. Arrested cultures were tested for three
markers of cell senescence: p16, b-galactosidase, and
senescence-associated heterochromatic foci (SAHF)
(Narita et al., 2003) – multiple foci of nuclear heterochro-
matin containing trimethylated lysine 9 of histone H3
(H3M3K9). Examples are shown in Figure 4 and Fig-
ures S2 and S3. Note that melanoma nuclei are small
and did not show distinct and separate SAHF as seen in
fibroblasts, so cells with irregular masses of bright stain-
ing for H3M3K9 were also counted positive (Figure S3),
as these were not generally seen in growing cultures.
All arrested lesional cultures, whatever their origin, were
positive for all three senescence markers (Table 1B),
while tested immortal cultures were generally negative
for all these markers (Figure 4). Not all cells within each
arrested culture were detectably positive, however,
although this is also true of normal senescent melano-
cyte cultures, in which 60–80% typically show senes-
cence markers (data not shown). Likewise, senescent
human fibroblasts showed between about 70–90%
staining for b-galactosidase (Dimri et al., 1995). In nevus
cells, p16 was often cytoplasmic as well as nuclear; this
pattern seems common when expression levels are
high, as also seen in nevi in vivo (Gray-Schopfer et al.,
A
B
C
D
Figure 3. Types of growth patterns for nevus and primary
melanoma cultures. Cultures that grew sufficiently to be
subcultured were counted at each subculture (Methods). The fold
increase for each passage was calculated and converted to
cumulative doublings from the first subculture; each point marks
one passage. Dermal-only fractions of lesions are shown, except
(ep): epidermal fraction of same lesion. Key: BCN, benign
compound nevus; ABN, atypical benign nevus (no dysplasia); and
DN, dysplastic nevus. (A, B) Initial growth followed by slowing and
arrest – the most common pattern. (C) Initially slow growth
followed by acceleration, seen only in immortal melanoma cultures
(here radial growth-phase lines SGM2 and SGM4). (D) Deceleration
followed by acceleration steps (arrows), in VGP culture SGM5. The
first acceleration followed reduction of the 12-O-tetradecanoyl
phorbol 13-acetate (TPA) concentration to 20 nM on obtaining of
dose–response data; the second was spontaneous. Arrest of both
portions of VGP culture SGM6 (despite reduced TPA) also shown.
Soo et al.
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2006; Michaloglou et al., 2005). p16 fluorescence typi-
cally appeared less intense in arrested RGP and VGP
than in nevus cultures and again was often cytoplasmic
(Figure S2), while the percentage of cells positive for
b-galactosidase declined significantly with progression
stage, to only around 20% of cells in VGP cultures
(Table 1B). The arrested RGP and VGP cultures also
showed atypical morphology, with giant, multidendritic,
and often multinucleate cells – also seen in nevus cul-
tures but less commonly (Figure 4, lower panels) – and
with noticeable cell death occurring. These features are
not typical of normal senescence and suggested the
possibility of telomeric crisis (where arrest represents
continuing division balanced by death, and strong
nuclear p16 expression would not be expected).
Features of crisis in uncultured melanomas
To test whether some primary melanomas may be at
or approaching crisis, a series of uncultured melanoma
sections was surveyed for anaphase bridges (dicentric
chromosomes attached to both mitotic poles), a useful
marker of crisis ⁄ telomere dysfunction (Artandi and DePin-
ho, 2010; Chin et al., 2004; DePinho and Polyak, 2004;
Gisselsson and Ho¨glund, 2005; Gisselsson et al., 2001).
Multinucleate cells and tripolar mitoses are also typical of
crisis, although less specific, and these were also scored.
All three features proved common in VGP melanomas
(Figure 5; Table 2). Remarkably, over 21% of all anapha-
ses in VGP lesions showed chromatin bridging. All three
features were uncommon in RGP sections, but then few
actual mitoses were observed here. This was consistent
with textbook accounts that RGP melanomas lack mito-
ses in the dermal portion, while the epidermal portion is
very thin (Mooi and Krausz, 2007), thus also providing
few mitoses for analysis. At any rate, most VGP melano-
mas in vivo exhibit evidence of telomere dysfunction, in
line with their lack of immortality in culture.
Long-lived and immortal cultures from early
melanomas: chromosomal changes, oncogenes,
and telomerase
Four new immortal lines and two long-lived cultures
were obtained from primary melanomas. These were
characterized by karyology, growth kinetics, and geno-
typing for the BRAF and NRAS mutations common in
melanomas and nevi (Table 3). SGM1 was a long-lived
Table 1. Growth arrest in relation to senescence markers in cultures explanted from pigmented lesions. (A) Growth outcomes of cultures by
lesion type. (B) Expression of senescence markers by all arrested cultures but not all cells
Diagnosis
Total successful
attempts (i.e.,
pure melanocytes)
Outcome (arrest or immortal)
Did not grow
enough to subculture
(in at least 6 weeks)
Grew, subcultured,
then stopped
(2 weeks to 6 months)
Continues to
grow – appears
immortal
(A)
Benign nevus 22a 7 15 0
Dysplastic ⁄ atypical nevus 6 4 2 0
RGP melanoma 22 11 8 3
VGP melanoma (reduced TPA) 15 6 7 1
Diagnosis
Proportion of arrested cultures positiveb Percentage of cells positive (mean, SEM)
b-galactosidase p16 H3M3K9 b-galactosidase p16 H3M3K9
(B)
Nevus 12 ⁄ 12 14 ⁄ 14 12 ⁄ 12 65.8 ± 2.08 59.9 ± 3.30 76.6 ± 3.41
RGP melanoma 7 ⁄ 7 6 ⁄ 6 (fainter) 5 ⁄ 5 50.0 ± 5.12 61.7 ± 6.10 72.5 ± 13.14
VGP melanoma 11 ⁄ 11 8 ⁄ 8 (fainter) 8 ⁄ 8 22.2 ± 2.47 62.7 ± 5.73 77.3 ± 8.39
H3M3K9, histone H3 trimethylated on lysine 9; RGP, radial growth-phase; VGP, vertical growth-phase.
aNumbers of cultures in each category are shown. The data represent accumulated experience over 4 years. On pooling categories, there was
a significant difference (P < 0.05) by the chi-squared test between the proportion of melanomas giving immortal cultures (5 ⁄ 37, 13.5%)
compared with the proportion of nevi (0 ⁄ 28).
bCultures that had arrested were trypsinized, plated on to sterile glass coverslips, and processed for cytochemistry (b-galactosidase) or by
immunostaining for markers of cell senescence (Methods). For % cells positive, 100–200 cells per lesional culture were counted where
possible, or otherwise as many as were visible. The percentage of cells positive may be an underestimate in some cases where staining may
have been masked by melanin. Only a single dysplastic nevus culture had enough surviving cells at arrest for analysis; this was pooled with
benign nevi. Intense fluorescence for H3M3K9 was counted as positive, whether or not multiple foci were distinguishable, as sometimes the
foci were crowded and hard to distinguish, and intense fluorescence was not seen in immortal cultures. Among these arrested cultures,
significantly fewer cells showed b-galactosidase staining in VGP than in nevus cultures (P = 4 · 10)8, very highly significant) and in VGP than
in RGP cultures (P = 0.0012, significant) (2-tailed t-tests with Bonferroni multiple testing correction). Other differences were not significant,
although p16 staining was visually judged to be typically fainter in melanoma than in nevus cultures.
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culture from an RGP melanoma; these cells became
arrested after about 6 months (Figure 3A), and no
chromosomal abnormalities nor oncogene activation
was detected. SGM2, SGM3, and SGM4 were RGP cul-
tures that appeared immortal. SGM2 grew faster with
increasing passage level, in at least two incremental
steps (Figure 3C). SGM4 showed similar increments in
growth rate after about 2 months, in both the epidermal
Figure 4. Expression of senescence markers and atypical morphology in arrested lesional cell cultures. Examples of marker-positive and
negative cultures as quantitated in Table 1(B). BN, Benign nevus cells; (RGP, VGP) radial growth-phase and vertical growth-phase melanoma
cultures. (arr, gro) Arrested and growing cultures. (b-gal, also bottom right image) Cultures stained for ‘senescence-associated’ b-galactosidase
(pH 7.0 as modified for melanocytes; Methods) (blue). Bars, 200 lm. Arrested VGP melanoma cultures typically showed cells ranging from
small, faintly pigmented, and unstained (arrow, top left panel) to large, flat, well pigmented, and well stained (arrowhead). Growing cells
typically negative. (p16 ⁄ Hoescht) Cultures immunostained for p16 (FITC, green), counterstained with Hoechst 33258. Bar, 50 lm. The larger,
flat, stellate cell has intense nuclear p16 masking the Hoechst 33258, while the other has mainly cytoplasmic p16. (Only nuclear p16 was
considered positive.) Growing VGP cells were completely negative. (H3M3K9) Cultures immunostained for heterochromatin marker histone
H3 trimethylated on lysine 9 (FITC, green). Bar, 50 lm. Green brightness digitally reduced in RGP panel to make senescence-associated
heterochromatic foci (SAHF) sharper. SAHF are positive for both H3M3K9 and Hoechst, giving cyan color. Growing VGP culture shows no
SAHF. Not counterstained, to show clearly the lack of foci and general paucity of heterochromatin. (Bottom 4 panels) Giant, multinucleate
cells in arrested cultures. High-magnification images seen by phase contrast (gray; bar = 100 lm), Hoechst 33258 (blue fluorescence;
bar = 20 lm) or bright-field optics with b-galactosidase stain (bar = 200 lm). Arrows indicate some of the micronuclei (pale), each with one or
more nucleoli (dark). Cell debris and floating or poorly attached cells are also seen (phase-contrast images), indicative of cell death.
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and one dermal portion of the lesion (Figure 3C), sug-
gesting that a small immortal subpopulation was pres-
ent initially and grew out in both fractions. SGM5 was a
VGP line that grew continuously, with acceleration at
higher passage levels (Figure 3D). Lines SGM2 to
SGM5 all had an activated allele of either BRAF or
NRAS and chromosomal aberrations (Table 3), minor in
SGM4 and SGM5. SGM6 was a VGP-derived culture
that grew slowly, finally arresting after 23 doublings and
10 months. No mutation of BRAF or NRAS nor karyolog-
ical change was detected in SGM6.
To investigate association between immortalization
and telomerase, we tested the immortal lines and a
selection of non-immortal cultures for telomerase activ-
ity by the telomerase repeat amplification protocol
(TRAP) assay and for the expression of the two subun-
its of telomerase, TERT and telomerase RNA compo-
nent (TERC) (the RNA component), by Q-PCR and also
by TERT splice-variant analysis. Two normal melanocyte
cultures and the non-immortal RGP-derived culture
SGM1 all expressed TERC, but none of these, nor
normal fibroblasts, had detectable full-length TERT or
telomerase activity (Figure 6). However, all tested
immortal lines (SGM2 to SGM5) did display both telo-
merase activity and full-length TERT as well as TERC
expression. Levels were comparable to those seen
in control metastatic melanoma lines (Figure 6A,C).
Lines positive and negative for full-length TERT by
splice-variant analysis were likewise positive and nega-
tive, respectively, by Q-PCR (data not shown).
A
C
B
D
E F
G H
Figure 5. Markers of crisis in uncultured vertical growth-phase
(VGP) melanomas. Sections of VGP melanomas from Cellular
Pathology archival blocks, stained with hematoxylin and eosin.
(A–D) Anaphase bridges (arrowed). Distinct bridge of chromatin
between the two anaphase plates. (E–F) Tripolar mitoses, in giant
cells (asterisks). (G–H) Multinucleate cells, arrowed. Bar for A–F,
25 lm; bar for G–H, 25 lm.
Table 2. Anaphase bridging and related abnormalities in primary
VGP melanomas
Melanoma
Breslow
thickness
(mm)
if >1 mm
% anaphase
bridges per
anaphase
Tripolar
mitoses
observed
Multinucleate
cells
observed
1 9.5 0 (0 ⁄ 5) Yes Yes
2 9 31 (10 ⁄ 32) Yes Yes
3 6 14 (3 ⁄ 21) Yes Yes
4 3.4 20 (3 ⁄ 15) Yes Yes
5 3.2 0 (0 ⁄ 1) No Yes
6 2.3 16.7 (6 ⁄ 36) Yes Yes
7 2.2 26.5 (9 ⁄ 34) Yes Yes
8 2.1 30 (3 ⁄ 10) Yes Yes
9 1.96 0 (0 ⁄ 1) No Yes
10 1.6 19 (3 ⁄ 16) Yes Yes
11 1.4 ? (0 ⁄ 0) No Yes
12 40 (2 ⁄ 5) Yes Yes
13 0 (0 ⁄ 5) Yes Yes
14 ? (0 ⁄ 0) Yes Yes
15 ? (0 ⁄ 0) No Yes
16 ? (0 ⁄ 0) No Yes
17 ? (0 ⁄ 0) No Yes
RGP, radial growth-phase; VGP, vertical growth-phase.
Anaphases and anaphase bridges were counted in hematoxylin-
and eosin-stained sections of seventeen VGP primary melanomas
from archived blocks at St. George’s Healthcare Trust, ranked here
by Breslow thickness. Frequency of bridging was high, totaling
21.5% of all anaphases seen. Anaphase bridges (Figure 5) were
present in all VGP sections with over five mitoses. Tumors were
also scored for the overall presence or absence of tripolar mitoses
and multinucleate cells. The presence of tripolar mitoses correlated
well with anaphase bridging, while multinucleate cells were
observed in all melanomas. Six RGP melanomas were analyzed in
the same way. However, percentage of bridging could not be
determined because no anaphases were found in these sections.
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Discussion
To clarify the basic mechanisms of melanoma initiation,
we directly tested the twin hypotheses that nevus cells
are senescent and melanoma cells are immortal, using
conditions optimized for survival and proliferation of
each lesion type. Under these conditions, benign and
dysplastic nevi both typically showed a little proliferation
and then senesced, displaying three markers of senes-
cence. However, the proliferation of nevus explants as
separate colonies suggested that only a small fraction
of explanted cells actually grew. This fraction might be
contaminating normal melanocytes, although because
they were equally common in dermal and epidermal
explants, this would require that normal melanocytes
commonly enter the dermal part of a nevus. At any rate,
division continued for a few passages at most, so even
these cells appeared nearly senescent. Moreover, the
nevi studied here were not quite typical, having all been
excised because of a clinical suspicion of malignancy,
although finally diagnosed as nevi. High-passage normal
human fibroblast cultures regarded as senescent con-
tained 4–8% of cells able to proliferate (enter S-phase)
(Seshadri and Campisi, 1990). If we similarly regard a
lesion in vivo as senescent if say <5% of the cells can
divide, then even though we saw some proliferating
cells, our findings are still consistent with describing
nevi as senescent. This accords completely with their
static nature and the expression of senescence markers
(Gray-Schopfer et al., 2006; Michaloglou et al., 2005).
Given the common belief that immortalization is nec-
essary for malignancy (Collado et al., 2007; Stewart and
Weinberg, 2006), we previously hypothesized that
immortalization initiates a melanoma (Bennett, 2003;
Gray-Schopfer and Bennett, 2006). However, we now
report that most primary melanoma cultures – despite
initially growing well under the optimized conditions –
later arrest. This arrest differs from normal senescence,
as senescence markers are less prevalent or faint, and
abnormal or multinucleate morphology and cell death
seem common. The level of p16 protein expression is
frequently low, as seen in uncultured melanoma sec-
tions (Gray-Schopfer et al., 2006; Keller-Melchior et al.,
1998; Talve et al., 1997). Senescence is known to be
defective in p16-deficient melanocytes (Ha et al., 2007;
Sviderskaya et al., 2002, 2003), leading in human mela-
nocytes to telomeric crisis in the absence of TERT (Svid-
erskaya et al., 2003). Thus, an attractive explanation for
the arrest, bizarre morphology and cell death in mela-
noma cultures is telomeric crisis. As a more specific
test of crisis, we looked for anaphase bridging and other
mitotic abnormalities in uncultured melanoma sections
and found that they were indeed common in VGP
melanomas.
Abnormal mitoses and pleomorphic cells are long-
established indicators of malignancy. However, there is
now good evidence to attribute many such mitotic
abnormalities, especially anaphase bridging, to telomere
dysfunction, implying that these particular cancer cells
would be in crisis and not immortal (Artandi and DePin-
ho, 2010; DePinho and Polyak, 2004; Gisselsson and
Ho¨glund, 2005; Gisselsson et al., 2001). Specifically,
telomeric crisis phenotypes (including anaphase bridg-
ing) have been reported to peak at the stage of carci-
noma in situ ⁄early adenocarcinoma in human breast and
colorectal cancers (Chin et al., 2004; Rudolph et al.,
2001) and to be common in overt carcinoma in the pan-
creas and ovary (Hezel et al., 2006; Ho¨glund et al.,
2003). Chin et al. (2004) nicely demonstrated parallels
between telomeric crisis in culture and in carcinoma in
situ, including a peak in gene copy-number variance.
There are other possible mechanisms that can yield
generally abnormal mitoses, for example S ⁄G2 or G2 ⁄M
checkpoint deficiencies, extra centrosomes, or misalign-
ment of chromosomes (Peddibhotla and Rosen, 2009).
However, these mechanisms do not give individual ana-
phase bridges. (Entering mitosis with incompletely repli-
cated DNA would give multiple bridging or no clear
Table 3. Long-lived and immortal primary melanoma cultures: characteristics
Cell line Sourcea Oncogene Karyotype
Shortest doubling
timeb (days)
SGM1 RGP None found Diploid 9.2
SGM2 RGP BRAF V600E Subtetraploid: 85, XXX, )1, )3, )6, )9, )9, der(13,14)(q10;q10) 2.8c (>passage 14)
SGM3 RGP BRAF V600E Tetraploid, translocations in 3p and 8q, unbalanced 3q and 4qd 4.9
SGM4 RGP BRAF V600K 46, XX, add(7)(q?36), add(17)(q?25) 3.8
SGM5 VGP NRAS Q61K 46, XY, der(9)t(9,13), +der(9)t(9,13), add(9)(p?24), )22 2.5
SGM6 VGP None found Diploid 6.3
BRAF, v-raf murine sarcoma viral oncogene homolog B1; RGP, radial growth-phase; SGM, St. George’s melanoma (line); VGP, vertical
growth-phase.
aDiagnosis based on sections adjacent to cultured portion.
bCalculated from steepest part of growth curve.
cor 5.3 days before passage 14.
dDetails obscured by abundant pigment. Line SGM1 was long-lived but did arrest, SGM2-5 were immortal, and SGM6 is long-lived, slow-
growing, and possibly immortal.
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anaphase.) Because abnormal mitoses (or any mitoses)
are very rare in nevi, and as RGP melanomas also have
few mitoses, it can at least be concluded that telomeric
crisis is rare in pigmented lesions less progressed than
the VGP. From this and the fact that immortalization is
unlikely before crisis (there would be no selective pres-
sure for it), the most probable conclusion is that immor-
talization does not typically occur before the VGP stage.
This is consistent with the cell-culture findings and quite
comparable to the above-cited evidence for crisis occur-
ring within various early carcinomas rather than before
their initiation.
Accordingly, we now propose a revised genetic model
of melanoma progression (Figure 7), in which immortali-
zation with TERT expression is not required for mela-
noma initiation as previously proposed but is associated
more with progression. (Note that such a model is only
a hypothesis to integrate current evidence, not a firm
conclusion.) Proliferating early melanomas would be
post-senescence but precrisis, as shown. As RGP mela-
nomas have few mitoses (Mooi and Krausz, 2007) and
exhibit localized p16 and ⁄or p21 in vivo (Gray-Schopfer
et al., 2006), they may retain some competence to
senesce in some areas, but presumably other areas
have evaded senescence and are growing, as a non-
growing lesion would not be diagnosed as a melanoma.
We have confirmed for the first time a separate pre-
diction of the earlier model, retained here: that RGP
cells are keratinocyte-dependent for survival. This is
interesting, as a potential explanation for the radial
growth pattern itself. Invasive growth could then arise
through a genetic or epigenetic alteration suppressing
apoptosis, such as loss of APAF1, PTEN, a number of
which are common in VGP melanomas (Figure 7) (Ben-
nett, 2008). Alternatively, a microenvironmental change
in which host stromal or reactive cells started to pro-
duce survival factors for the melanoma cells might
achieve the keratinocyte independence.
Mechanisms other than crisis might mediate arrest in
melanoma cultures. Perhaps it could have been an arti-
fact of explantation. For example, mouse fibroblast
senescence has been attributed to stress by atmo-
spheric oxygen level (Parrinello et al., 2003). How-
ever, human diploid fibroblasts still senesce in hypoxic
A
B
C
Figure 6. Expression of telomerase subunits and activity in non-
immortal and immortal melanocytic cultures. (A) expression of full-
length telomerase reverse transcriptase (TERT) from splice variant
analysis. Mean and range of duplicates. Qualitatively similar results
were obtained by Q-PCR, though with greater variability (not
shown). All melanoma lines that expressed full-length TERT also
expressed the inactive b-deletion splice variant but little or no
dominant negative a-deletion variant (data not shown). (B)
Telomerase RNA component expression by Q-PCR. Mean and
SEM of triplicate cultures, with duplicate readings from each. (C)
telomerase activity by the telomerase repeat amplification protocol
assay. Mean and SEM of six readings, three each from two
experiments. NHM, normal human melanocytes; NHF, normal
human dermal fibroblasts. SGM lines: see Table 3. WM1158 and
451Lu: established metastatic melanoma lines. HT1080 and KMST-
6: positive and negative control lines.
Figure 7. Proposed update of model for melanoma progression.
Revised from model of Bennett (2003). Red lines indicate additional
genetic changes proposed for each lesion type compared to less
progressed lesions. Dashed lines indicate not in all lesions. Benign
nevi are still regarded as senescent lesions. Primary melanomas
are still assumed to have escaped normal p16 ⁄ RB-based
senescence but are now proposed to be typically pre- or pericrisis
rather than immortal. Activation of telomerase is now proposed as
a late event, conferring immortality, and (from literature cited)
common in metastatic melanoma.
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conditions (Chen, 2000). The difference may be con-
nected with the fact that human cells require the activa-
tion of telomerase for immortality, unlike mouse cells.
Moreover, normal neonatal melanocytes and also adult
p16-deficient melanocytes will grow for 50 doublings or
more under these conditions (Sviderskaya et al., 2003),
while metastatic melanomas frequently do yield immor-
tal cultures at ambient oxygen levels (Hsu et al., 2000;
Semple et al., 1982). Thus, a fairly short lifespan at
ambient oxygen levels appears to be a typical property
of primary melanoma and nevus cells, but not of meta-
static melanoma cells and normal melanocytes, reveal-
ing a consistent biological difference.
It is possible that this limited lifespan of early melano-
mas is observed only in cell culture. Quintana et al.
(2008, 2010) reported that 30% of all cells from uncul-
tured human melanomas could form tumors if implanted
in Matrigel in immunodeficient mice, and where tested,
these tumors could be serially transplanted, indicating
immortality. However, nearly all these melanomas were
either metastases, previous xenografts, or stage III
(metastatic) primary melanomas. To date, only one
stage II (non-metastatic) melanoma was tested (5 ⁄6
groups of 10 cells formed tumors) and no stage I, which
includes RGP melanomas (Quintana et al., 2010). Thus,
as the authors state, more work is needed to assess
the tumorigenic and proliferative potential of early-stage
melanoma cells. The findings strengthen the idea that
metastatic melanoma cells are typically immortal.
Perhaps immortal cells were sometimes present but
were inhibited by our conditions. TPA and SCF inhibit
the growth of some metastatic melanomas (Hsu et al.,
2000; Zakut et al., 1993), and some immortal VGP lines
grow in simpler media than ours (Herlyn et al., 1985a;
Hsu et al., 2000; Pope et al., 1979; Semple et al., 1982).
We did initially vary the conditions, including omitting
growth factors, and observed growth stimulation rather
than inhibition by the growth factors. Moreover, the fre-
quency of establishment of melanoma lines from small
samples in such simpler media by the highly experi-
enced Wistar group (Hsu et al., 2000) was apparently
no higher than ours. Still it remains possible that condi-
tions optimized for growth rate may not be optimal for
lifespan. This can be tested in future by explanting mel-
anoma metastases, at least some of which contain
immortal cells, in a medium optimized for their initial
growth, as well as in the medium used here for VGP
cells. Again, melanomas are heterogeneous, and immor-
tal cells might be in the lesions but missing from the
fragments cultured. However, we based the sample
diagnosis on adjacent sections, so the explant should
generally correspond to this diagnosis. The conditions
used here were optimized for the bulk population in
freshly explanted lesional cultures. Thus, we can con-
clude that this bulk population is not usually immortal
under these conditions. The melanoma lines we did
obtain had minimal-deviation karyotypes and phenotypes
and seem to provide needed representatives of early
stages of oncogenesis.
Can a cancer be non-immortal? This departs from the
dogma that cellular immortality is a hallmark of cancer.
However, as cited earlier, crisis (preimmortal) pheno-
types have been reported before in a range of early
human cancers, providing some precedent for the possi-
bility (Hezel et al., 2006; Ho¨glund et al., 2003). More-
over, non-immortal human cells including melanocytes
may undergo 50 or more population doublings (Bennett
and Medrano, 2002), yielding potentially over a tonne of
cells if none died. A mutant cell could thus theoretically
proliferate into a typical metastatic tumor bulk without
immortalization. However, immortality does appear com-
mon in advanced cancers, including metastatic mela-
noma, perhaps because oncogenes accelerate
senescence and ⁄or because many lesional cells do die.
We present initial evidence here that this immortaliza-
tion is associated with progression rather than initiation
of melanoma.
Methods
Materials
Gibco culture media and FCS were obtained from Invitrogen Ltd,
Paisley, UK. NUNC tissue culture plastics were from Fisher Scien-
tific (Loughborough, UK). TPA, CT, mitomycin C, and other
reagents were from Sigma-Aldrich Co. (Poole, UK). Human SCF
was from R&D Systems Europe (Abingdon, UK) or Invitrogen and
EDN1 from Bachem (Weil am Rhein, Germany).
Primary culture of clinical pigmented lesions
See Data S1 and Soo et al. (in press) for more details. ‘Growth
medium’ for lesional cells was RPMI 1640 with penicillin
(104 U ⁄ ml), streptomycin (100 lg ⁄ ml), glutamine (2 mM), extra
phenol red (7.5 lg ⁄ ml), 10% FCS, 200 nM TPA (20 nM TPA for
VGP cells once diagnosed), 200 pM CT, 10 ng ⁄ ml SCF, and 10%
CO2, unless otherwise stated. Mitomycin-inactivated XB2 mouse
keratinocytes were plated at 5 · 105 ⁄ ml, 0.5 ml ⁄ well, into a
24-well culture plate, in DMEM with 10% FCS. Melanocytic lesions
were obtained directly after surgery, with all subjects’ informed
consent, from St. George’s’ Pigmented Lesions and Plastic Surgery
clinics. They were transported in chilled medium to a consultant
pathologist for assessment. If permitted, a sliver of tissue was cut
for culture, leaving the rest for diagnosis.
Epidermal and dermal portions were separated from the speci-
men as described in Data S1, dissociated, and plated in growth
medium (0.5 ml ⁄ well) on to the feeder cells: three wells for the
dermal and one for the epidermal suspension. The cultures were
incubated at 37C, with fresh medium twice weekly, and subcul-
tured as described in Data S1.
Established SGM lines were grown in the same growth medium,
except that for the VGP line SGM5, RPMI1640 was mixed 1:1 with
DMEM and the TPA concentration was 20 nM.
Other cell cultures
All cultures were grown at 37C with 10% CO2 in air. Normal
human melanocytes were from our stocks or Cascade Biologics
melanocytes were purchased from Invitrogen Ltd. They were
grown as described (Gray-Schopfer et al., 2006), in the above med-
ium plus EDN1 (10 nM). Human metastatic melanoma lines
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WM1158 and 451Lu were a gift from M. Herlyn and were grown
in RPMI 1640 and 10% FCS. Normal human dermal fibroblasts
were grown in DMEM and 10% FCS.
Assays of growth and apoptosis
For growth curves, triplicate hemocytometer counts were taken
at subculture. The fold increase since plating was calculated and
converted to population doublings, which were plotted cumula-
tively. For short-term assays of proliferation, cells were plated in
triplicate 3-cm dishes in each test medium; media were renewed
twice weekly. Cultures were harvested after the stated period;
duplicate hemocytometer counts per dish were used to calculate
mean and SEM of cell numbers. To assess apoptosis, cells were
plated in triplicate 3-cm dishes at 3 · 104 cells ⁄ ml and grown
with the indicated supplements for about 5 weeks. Cells were
harvested with trypsin, chilled, pooled with the medium from the
same dish (containing any detached cells), centrifuged, and
resuspended in PBS containing 1% FCS. They were counted by
hemocytometer and resuspended at 5 · 104 cells ⁄ ml. They were
spun on to glass slides in a Cytospin unit (Universal 320, Hettich
Zentrifugen; GMI Inc., Ramsey, MN, USA), air-dried, fixed in 4%
formaldehyde, washed twice in calcium- and magnesium-free
Dulbecco’s PBS (PBSA; pH 7.2), post-fixed in 2:1 ethanol:acetic
acid at )20C, and washed twice in PBSA. Terminal deoxynucle-
otidyl transferase dUTP nicked-end labeling (TUNEL) staining was
performed with an Apoptag kit using fluorescein detection (Milli-
pore, Billerica, MA, USA), according to the manufacturer’s
instructions. Nuclei were counterstained with Hoechst 33258,
specimens mounted in Citifluor antifade medium (Citifluor Ltd,
Leicester, UK), and apoptotic cells counted by two different
observers, whose counts were similar and were averaged for
each slide.
b-galactosidase staining
In subdued light, 1 mg ⁄ ml X-gal solution (5-bromo-4-chloro-3-indol-
yl-b-galactopyranoside; Sigma-Aldrich Co), 0.12 mM K3Fe(CN)6,
0.12 mM K4Fe(CN)6, and 1 mM MgCl2 in PBSA, pH 7.0, were pre-
pared. Cells were washed in PBS (complete Dulbecco’s PBS with
CaCl2 and MgCl2, pH 7.2) and fixed with fresh 0.5% glutaraldehyde
in PBS for 5 min at room temperature. Washed again, the cells
were stained with X-gal solution (pH 7.0) for 24 h at 37C in air.
The pH is modified from Dimri et al. (1995) because growing mela-
nocytes also often stain at pH 6.0; Gray-Schopfer et al., 2006).
Senescent normal human melanocytes were the positive control.
Cells were viewed in water and photographed using an Olympus
IMT-2 inverted microscope (Olympus, Southend-on-Sea, UK).
Immunofluorescence
Cells were grown on glass coverslips in a 4-well plate, or primary
cultures in their original 24-well plate were cut out using a heated
scalpel. Subconfluent cells were washed in PBS. They were fixed
with fresh 3.7% formaldehyde in PBS for at least 20 minutes and
permeabilized with 0.5% Triton X-100 for 5 min [except fixation
was with fresh 4% paraformaldehyde for H3M3K9 staining]. After
blocking with 10% FCS in PBSA for 1.5–2 h, cells were incubated
with primary and FITC-conjugated secondary antibodies in 1% BSA
in PBSA at room temperature for 1 h each. Antibodies and concen-
trations were as follows: mouse anti-p16 (NeoMarkers, Newmar-
ket, UK) (1:50) with anti-mouse IgG (FITC) (Sigma-Aldrich) (1:50)
and rabbit anti-histone H3 trimethylated on lysine 9 (H3M3K9)
(ab8898; Abcam plc, Cambridge, UK) (1:5000) with goat anti-rabbit
IgG (FITC), (ab6717; Abcam) (1:200). Cells were washed three
times (5 min) in complete PBS and counterstained with Hoechst
33258 (0.2 lg ⁄ ml for 10 min). They were rinsed in water and
mounted in Citifluor. Photography was with an Axioplan 2 fluores-
cence microscope and AxioVision 3 digital imaging (Carl Zeiss Ltd,
Welwyn Garden City, UK).
BRAF and NRAS genotyping
Amplification of BRAF exon 15 and NRAS exon 2 and 3 was
performed using the following primers (20 lM): BRAF exon 15:
forward, TCATAATGCTTGCTCTGATAGGA and reverse, GGCCAAA-
AATTTAATCAGTGGA. NRAS exon 2: forward, GAACCAAATGGAAG-
GTCACA and reverse, TGGGTAAAGATGATCCGACA. NRAS exon 3:
forward, CAATAGCATTGCATTCCCTGTG and reverse, CTAGTGTGG-
TAACCTCATTTCCC. PCR products were electrophoresed through a
2% agarose gel containing ethidium bromide (50 lg ⁄ ml) at 100 V
for 40 min. The appropriate bands were excised, and gel purifica-
tion was performed using a Quick Clean DNA gel extraction kit
(Qiagen) as per instructions. DNA was eluted in 20 ll of TE buffer.
Automated DNA sequencing was performed using the same prim-
ers (3.2 pmol).
TERT mRNA and TERC expression analysis
Q-PCR (Atkinson et al., 2005) was carried out in triplicate using the
Opticon 2 DNA engine and software (MJ Research Inc., Waltham,
MA, USA). SYBR green was the fluorophore. TERC (hTR) expres-
sion was quantitated using the primers: TRC3F, 5¢- TAACCCTAA-
CTGAGAAGGGCGTA-3¢ and TRC3R, 5¢-GGCGAACGGGCCAGCAGC-
TGACATT-3¢. It was normalized to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA (primers: GAPDH0.45F: 5¢-AC-
CACAGTCCATGCCATCAC-3¢ and GAPDH0.45R: 5¢-CCACCACCCT-
GTTGCTGTA-3¢). TERT full-length expression was measured against
a standard curve generated using the pBABE vector with a TERT
cDNA insert (genomic DNA was used as standard for all other
Q-PCR reactions) (primers: TERTFULLF: 5¢-CATCCCCCAGGACAGGC-3¢
and TERTFULLR: 5¢-CTGTCAAGGTAGAGACGTGGCT-3¢). This was
then normalized to GAPDH mRNA level. TERT splice-variant
expression was analyzed according to Keith and Hoare (2004),
using primers that detect all splice variants (primers: HT2026F
5¢-GCCTGAGCTGTACTTTGTCAA-3¢ and HT2482R 5¢-GCCAAACAG-
CTTGTTCTCCATGTC-3¢). Products for the four main splice variants
(full length, a-deletion, b-deletion, and ab-deletion) were analyzed
using the Agilent Bioanalyser 2100 and DNA-1000 assay chips
(Agilent Technologies, Santa Clara, CA, USA).
Telomerase repeat amplification protocol assays
The method was according to Bilsland et al. (2009). The TRAPeze
XL kit was used, following the manufacturer’s instructions (Milli-
pore, Watford, UK). Cell pellets were lysed in CHAPS buffer and
protein concentration was estimated using the Bio-Rad assay (Bio-
Rad Laboratories Ltd, Hemel Hempstead, UK). A concentration of
0.5 lg protein was mixed with the TRAPeze reaction mix contain-
ing the TS primer, fluorescein-labeled RP primer, control template,
and sulforhodamine-labeled control K2 primer. Each assay included
no-telomerase, no-Taq, and heat-treated controls. Extension prod-
ucts were generated at 30C, followed by Q-PCR detection in tripli-
cate using the Chromo4 equipment and software (BioRad). Total
product generated was measured against the TR8 standards. (The
internal control was used to check that PCR was not inhibited, not
for normalization.)
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